The Ministry of Health of the Russian Federation has developed a draft law on the introduction of mandatory ethical review for biotechnological medicinal products (BTMP), which will take effect on September 1, 2026. The document was published for public discussion on Wednesday.
According to the draft, a special committee will be created to assess the use of such drugs. BTMPs are made individually for each patient in a medical organization using their own cells or tissues. They are used to treat life-threatening diseases, including oncological, autoimmune, and cardiovascular diseases.
As indicated in the explanatory note, the purpose of the ethical review is to guarantee the safety and protection of patients' rights. The committee will assess the appropriateness of the drug's use, the patient's awareness of the risks and benefits, and the absence of conflicts of interest.
The initiative was prepared on the instructions of Deputy Prime Minister Tatyana Golikova. Currently, such drugs are used selectively, mainly in federal centers as part of scientific research or internal protocols.
Read more on the topic:
Rostec supplied 85 thousand units of equipment to medical institutions in the country
Now on home
Start of deliveries scheduled for 2027
Over 51,000 new motorcycles were sold in Russia in 2025
The car will take at least a year to assemble
The application's audience has reached 20 million users
The model will be included in the list of cars for taxis, price - from 2.25 million rubles
All parking lots of the "Administrator of the Moscow Parking Space" are connected to the service
The cars will be supplied to the Moscow Transport Service Directorate
Deliveries to India may begin in 2028
The technology provides automated search for all types of defects in power units
The plane flew 500 km, accelerating to 425 km/h
The plant stated that the information about the termination of purchases for models 6 and 8 is not true
Scientists are using the "Ekran-M" installation